Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2279

2.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
3.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
5.
6.

The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.

Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B.

Neurology. 1997 Jun;48(6):1511-7.

PMID:
9191757
7.

Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.

Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C.

Curr Alzheimer Res. 2005 Jul;2(3):343-53.

PMID:
15974900
8.

Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.

Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R.

Methods Find Exp Clin Pharmacol. 1999 Nov;21(9):633-44.

PMID:
10669911
11.
12.

A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.

Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Herrmann WM.

Neuropsychobiology. 1997;36(2):73-82.

PMID:
9267856
13.

Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).

Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR.

Alzheimer Dis Assoc Disord. 1998 Dec;12(4):304-12.

PMID:
9876958
14.

A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population.

Suh GH, Yeon Jung H, Uk Lee C, Hoon Oh B, Nam Bae J, Jung HY, Ju YS, Kil Yeon B, Park J, Hong I, Choi S, Ho Lee J; Korean Galantamine Study Group.

Clin Ther. 2004 Oct;26(10):1608-18.

PMID:
15598477
15.

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J.

Arch Neurol. 2006 Oct;63(10):1402-8.

PMID:
17030655
16.

Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial.

Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M.

J Clin Pharm Ther. 2003 Feb;28(1):53-9.

PMID:
12605619
18.

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.

Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV; GAL-INT-6 Study Group.

Clin Ther. 2003 Jun;25(6):1765-82. Erratum in: Clin Ther. 2003 Aug;25(8):2336.

PMID:
12860497
19.
20.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603

Supplemental Content

Support Center